340B Entry Raised Off-Campus Outpatient Claims Even Under Site-Neutral Payment
The financial pull of the 340B Drug Pricing Program did not disappear when Medicare lowered payment differences at certain outpatient sites. In a cohort study spanning 2016 through 2019, hospitals that newly entered 340B in 2019 increased service volume at newly established off-campus hospital outpatient departments even though those departments were subject to site-neutral payment.
The effect was concentrated, measurable, and policy-relevant. At those off-campus sites, 340B entry in 2019 was associated with an average increase of 83.4 claims per hospital-quarter for overall volume and 12.8 claims per hospital-quarter for drug administration claims, compared with hospitals that did not enter the program. The probability of recording more than one claim per hospital-quarter rose by 11.6%, and the probability of recording more than one drug administration claim per hospital-quarter rose by 8.8%.
A Policy Environment Built Around Overlapping Incentives
The central question was not whether hospitals respond to payment incentives. They do. The question was whether 340B participation added an independent push toward vertical integration after site-neutral reforms were already in place to dampen the advantage of hospital ownership over physician-based outpatient care.
That distinction matters in practice because Medicare payment rules often operate in layers. Site-neutral payment was designed to narrow the spread between hospital-owned outpatient departments and other sites of care. The 340B program, by contrast, gives eligible hospitals access to discounted outpatient drugs, creating a separate revenue incentive tied to where care is delivered and how outpatient services are organized. When those incentives overlap, a reform targeting one channel can be diluted by another.
Claims Growth Was Specific to Newly Established Off-Campus Departments
Investigators analyzed 23,304,033 Medicare fee-for-service outpatient claims from 901 hospitals, including 122 hospitals that newly initiated 340B participation and 779 nonparticipating hospitals. They used difference-in-differences methods to compare changes over time in hospitals entering 340B with changes in hospitals that did not participate. The data covered 2016 through 2019, a period that captured site-neutral payment reforms and shifts in 340B drug reimbursement.
A clear pattern emerged in the 2019 cohort. The increase in claims was seen at newly established off-campus hospital outpatient departments subject to site-neutral payment, not across every outpatient setting. No significant changes appeared in other settings. This narrow distribution of effects is important because it points to behavior at the margin, where hospitals decide whether to expand outpatient infrastructure, redirect services, or deepen integration with physicians.
One sentence captures the operational consequence: hospitals moved activity toward the very sites where payment reform was supposed to blunt expansion incentives.
Why Drug Administration Claims Matter for Vertical Integration
Drug-related and drug administration claims serve as more than billing artifacts. In outpatient oncology, infusion medicine, rheumatology, gastroenterology, and other specialties where infused or administered therapies are common, a rise in these claims often signals greater hospital control over service delivery. More claims can reflect more visits routed through hospital-owned departments, more centralized administration of therapies, and a stronger institutional footprint around physician practice patterns.
That mechanism fits the logic of vertical integration. Hospitals may seek to capture drug margin, control ancillary billing, and consolidate outpatient care under their own organizational umbrella. Once a hospital is enrolled in 340B, the discounted acquisition cost of outpatient drugs can strengthen the economics of bringing more services inside the hospital system, even when Medicare payment differences have been narrowed at the site level.
The study did not show broad increases everywhere. It showed a selective rise where the financial structure made integration most attractive.
2019 Drove the Observable Signal, Not 2017
Hospitals newly entering 340B in 2019 showed the significant increases in overall claims and drug administration claims at newly established off-campus outpatient departments. The 2017 entrants did not produce the same significant pattern in the abstracted results. The report did not provide a mechanistic explanation for why the 2019 group showed the effect while the earlier cohort did not, but the timing places the observed signal squarely in a period when site-neutral payment reforms and 340B reimbursement changes were colliding.
That temporal pattern suggests policy context shaped behavior. If a hospital joins 340B when the reimbursement environment has already changed, the added incentive may become visible only in the most economically responsive outpatient settings. Off-campus departments subject to site-neutral payment appear to have been one such setting.
Policy Reforms Do Not Operate in Isolation
The findings carry a direct lesson for payment design: a reform aimed at reducing spending can be offset when another subsidy or pricing rule continues to reward the same organizational behavior from a different angle. Site-neutral payment was intended to reduce incentives for hospitals to expand outpatient service lines simply to capture higher facility payments. The 340B program, however, can continue to reward outpatient drug dispensing and administration within hospital-owned settings.
For clinicians and administrators, the practical consequence is structural. Service location, ownership, and billing pathway all influence how outpatient care is delivered and financed. In hospital systems with access to 340B pricing, the margin attached to administered drugs may still make consolidation attractive, particularly in departments where infusion-based care generates repeated encounters and ancillary revenue.
What the Data Can and Cannot Prove
This was a cohort study, not a randomized trial, so the findings show association rather than experimental causation. The difference-in-differences design strengthens the inference by comparing changes over time between newly participating and nonparticipating hospitals, but it cannot fully eliminate every unmeasured factor that might move hospitals toward integration at the same time they enter 340B.
Even so, the direction of effect is consistent with the policy logic. The increase was not diffuse. It was concentrated in newly established off-campus hospital outpatient departments subject to site-neutral payment, exactly the setting where a hospital would be expected to test whether a new financial incentive can outweigh a reform meant to reduce expansion pressure.
The main clinical and policy question left by this work is not whether payment rules matter. They do. The harder question is which combinations of reforms can actually neutralize the incentives that drive hospital-physician integration, rather than simply shifting those incentives into a different billing channel.